Scientific article


Published inRevue médicale suisse, vol. 7, no. 278, p. 138-144
Publication date2011

Calcium supplements should be used according to the dietary intakes. Daily vitamin D supplements have beneficial on bone and extraskeletal effects. Denosumab is registered in Switzerland for the treatment of postmenopausal osteoporosis and to prevent bone loss induced by sex hormone deprivation therapies in men and women. Zoledronate has a long-term efficacy on bone resorption in postmenopausal women and prevents bone loss induced by sex hormone deprivation therapies in both sexes. Teriparatide exerts beneficial effects on maxillary bone. Odanacatib decreases bone resorption and increases bone mineral density. Cinacalcet could be used as long-term treatment in case of hyperparathyroidism. Adverse events associated with the use of bisphosphonate are still under discussion. Strontium ranelate will not be introduced in Switzerland.

  • Bone Density Conservation Agents/therapeutic use
  • Calcium, Dietary/administration & dosage
  • Humans
  • Osteoporosis/prevention & control
  • Vitamin D/therapeutic use
Research group
Citation (ISO format)
UEBELHART, Brigitte Florence, RIZZOLI, René. Ostéoporose. In: Revue médicale suisse, 2011, vol. 7, n° 278, p. 138–144.
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation10/12/2013 12:02:00
First validation10/12/2013 12:02:00
Update time14/03/2023 20:42:12
Status update14/03/2023 20:42:12
Last indexation16/01/2024 8:27:35
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack